AFT Pharmaceuticals’ shares fall as drug fails FDA threshold

AFT Pharmaceuticals’ shares fall as drug fails FDA threshold
AFT Pharmaceuticals managing director Hartley Atkinson still believes Pascomer shows promise. (Image: AFT Pharmaceuticals)
Riley Kennedy
AFT Pharmaceuticals’ shares have fallen this morning after the company said a drug it is developing to treat facial angiofibromas (FA) had failed to reach the threshold for US Food and Drug Administration (FDA) registration.The company’s shares declined 3.3% to $3.80 in morning trading, after the pharmaceutical company released the findings of its study of its orphan drug Pascomer, which it said found “statistically significant” benefits. However, it did not reach the threshold on the IGA scale – a five-point...

More Markets

Trump-era FX 'compounding' margin losses, analysts say
Retail

Trump-era FX 'compounding' margin losses, analysts say

"Liberation day" could make matters worse, says Kiwibank’s Kerr.

The simple strategy behind Dairyworks
Primary Sector

The simple strategy behind Dairyworks

Is New Zealand still fixated on the 1kg block of cheese?

NZ sharemarket up 0.3%, Tower dominates trading
Markets Market Close

NZ sharemarket up 0.3%, Tower dominates trading

The S&P/NZX 50 Index closed at 12,312.6, up 42.6 points or 0.35%.

Graham Skellern 01 Apr 2025
Behind the rise of shareholder activism
Markets

Behind the rise of shareholder activism

Activists can be seen as 'baddies', but a new report says there are benefits.